{"id":"NCT02741115","sponsor":"Mezzion Pharma Co. Ltd","briefTitle":"Fontan Udenafil Exercise Longitudinal Assessment Trial","officialTitle":"Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-22","primaryCompletion":"2018-12-27","completion":"2019-04-30","firstPosted":"2016-04-18","resultsPosted":"2025-05-21","lastUpdate":"2025-06-17"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Single Ventricle Heart Disease"],"interventions":[{"type":"DRUG","name":"Udenafil","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drug","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent subjects who have undergone the Fontan procedure.","primaryOutcome":{"measure":"Change in Maximal VO2 From Baseline to Week 26 Using Last Observation Carried Forward (LOCF)","timeFrame":"Baseline to 26 Weeks","effectByArm":[{"arm":"Udenafil","deltaMin":-0.23,"sd":4.056},{"arm":"Placebo","deltaMin":-0.89,"sd":3.672}],"pValues":[{"comp":"OG000 vs OG001","p":"0.092"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States","Canada","South Korea"]},"refs":{"pmids":["36378780","31736357","29910047"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":200},"commonTop":["Headache","Upper Respiratory Tract Infectins","Flushing","Dizziness","Epistaxis"]}}